A biobank is a facility that stores biological samples, blood, tissue, DNA, plasma, cell lines, for research use over years or decades rather than the days or weeks a typical cold chain shipment runs on. Physically it is rooms of ultra-low freezers holding product around -80°C, banks of liquid nitrogen tanks holding samples in vapor or liquid phase at cryogenic temperatures near -196°C, and sometimes conventional frozen and refrigerated storage for shorter-lived sample types, all built along the same lines as any cold storage warehousing operation but rated for far colder set points and much longer dwell times. The defining difference from most cold chain storage is time horizon: a biobank sample is not moving toward a delivery date, it is sitting in place, sometimes for the rest of a research career, waiting to be useful to a study that has not been designed yet.
That long horizon changes what matters. A shipment-focused cold chain optimises for surviving one trip intact. A biobank optimises for surviving indefinitely in storage without degrading and for being findable and retrievable years after it went in, a genuinely different operational problem even though the equipment, an ultra-low freezer or a cryogenic tank, looks similar to what a hospital or lab already uses. A sample only needed for days before analysis does not need any of this: normal frozen or refrigerated storage covers it, and biobank-grade infrastructure earns its cost only once a sample has to stay viable and findable for years past any single study's timeline.
Ultra-low and cryogenic storage
Most biobank samples sit at one of two temperature points. Around -80°C, held in mechanical ultra-low freezers, suits most tissue, plasma, and extracted DNA or RNA, where cellular structure does not need to be preserved intact. Cryogenic storage, samples held in liquid nitrogen or its vapor phase near -196°C, is reserved for viable cells and anything that has to survive thawing and remain biologically functional afterward, since ice crystal formation at less extreme cold can rupture cell membranes that -80°C storage alone does not fully prevent. Choosing between the two is a sample-type decision made once at the point of collection, because moving a sample from one storage regime to the other after the fact, once it has already been frozen under one method, is rarely straightforward and can itself damage the sample.
Inventory systems built for decades
A biobank inventory system has to track a sample's exact physical location, down to a specific freezer, shelf, box, and grid position, for as long as that sample exists, through equipment replacements, facility moves, and staff turnover measured in decades rather than months. Barcoded tubes and boxes scanned into a database at every retrieval and return are standard, because a sample that cannot be physically located again is functionally lost even if it is still sitting frozen somewhere in the building. The system also has to carry consent and usage restrictions alongside location, since many samples come with limits on what research they can be used for, and losing that link is as serious a failure as losing the sample's location.
Freezer failure contingency
An ultra-low freezer or cryogenic tank failing is not a minor event; it threatens years of irreplaceable sample collection in one incident, since a research sample, unlike a drug product, usually cannot be reordered from a manufacturer. Biobanks plan around this with continuous temperature monitoring and alarms tied to on-call staff response, backup power for mechanical freezers, and for cryogenic tanks, a liquid nitrogen supply monitored separately from the electrical system entirely, since a nitrogen tank keeps samples cold through a power cut in a way a mechanical freezer cannot. Many facilities also split a collection across more than one freezer or site specifically so a single equipment failure cannot wipe out an entire sample set, treating physical redundancy as cheaper than losing the collection outright.
Sample integrity over decades
A biobank's core promise is that a sample pulled out in twenty years is scientifically usable, which depends on avoiding even brief temperature excursions that a shipment might absorb without consequence. Repeated freeze-thaw cycles, a box pulled out to retrieve one tube and left on a bench too long before returning, degrade sample quality cumulatively even when no single event looks dramatic on its own. This is why biobanks favour minimal-handling retrieval methods and split large samples into smaller single-use aliquots at the point of storage, so retrieving one aliquot for a study never requires warming and re-freezing the rest of a sample that other researchers might need intact later.
Retrieval workflows
Pulling a sample out for a study means locating it in the inventory system, retrieving the physical tube or vial with minimal time outside its storage temperature, and often shipping it onward in a validated insulated shipper packed with dry ice or a dry vapor shipper if it has to travel between institutions. That outbound leg briefly turns a static storage problem into an ordinary cold chain shipment problem, and the sample is exposed to the same risks any frozen shipment faces during that short window even though it spent years sitting still beforehand. Research institutions, university and hospital biobanks, and pharmaceutical R&D biobanks supporting clinical trial programs all run some version of this workflow, handing samples to couriers only for that short outbound window, with the same temperature excursion risks and documentation expectations any frozen shipment carries once it leaves controlled storage.